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There is growing recognition that the current research-and-development (R&D) and innovation-regulation
ecosystem could be made more efficient to stimulate and support access to innovative therapies for those patients
with rare, life-threatening diseases for which there are no adequate licensed therapies. New and progressive thinking
on the principles and processes of drug development and regulation are needed in rare disease settings in order to
ensure developments are financially sustainable. This paper presents perspectives on the current and emerging
schemes for accelerating development of and access to medicines for rare diseases in the European Union.
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Rare diseases represent a key challenge to healthcare sys-
tems. With less than 2% of identified rare diseases cur-
rently covered by approved treatments, the rare diseases
population is underserved. There is a need to increase the
number of rare diseases treated and to achieve this end in
a financially sustainable manner. Regulatory authorities,
patient groups, pharmaceutical companies, legislators and
payers collectively face the dilemma of how best to help
achieve more timely access to new effective treatments for
patients with chronically debilitating and life-limiting con-
ditions. Collaborative dialogue between all stakeholders is
essential and is already identifying issues and informing the
debate on a number of topics. Issues include how to adapt
clinical trial and research mechanisms to suit rare disease
settings while retaining the necessary rigors of evidence-
based medicine. There needs to be debate on how post-
authorisation evidence-gathering and collection of non-
randomised trial evidence might help expedite access to
orphan medicinal products (OMPs). An additional issue is
how to sustain investment in innovative research while* Correspondence: uguen@voisinconsulting.com
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reproduction in any medium, provided the orensuring access can be afforded by healthcare systems. Im-
proving access to OMPs should not come at an inflated
cost – patients, payers and drug developers should each
derive value from genuine therapeutic advances [1]. These
topics are broader than the regulatory debate on adaptive
licensing that is being piloted and championed by the
EMA, and extend beyond the market access sentinel of
health technology appraisals. The very rare and serious na-
ture of the clinical conditions in which OMPs are investi-
gated affects not only the type of clinical research that can
be undertaken, but also typically influences the patient per-
spective on the benefit:risk profile of a health technology.
This paper provides a contemporary overview of how rare
diseases and OMPs challenge purely gatekeeper-concepts
of regulation and market access, by embracing multi-
stakeholder views and taking a dynamic and fresh look at
how best to integrate knowledge, evidence and experience
in order to meet rare disease needs.
Licensing mechanisms
There are two European mechanisms by which an orphan
medicinal product (OMP) can currently be fast-tracked
through the licensing system - these are registration
under-exceptional-circumstances (EC) and the granting ofLtd. This is an Open Access article distributed under the terms of the Creative
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applicable when there appears to be a positive benefit:risk
balance for a drug but comprehensive efficacy and safety
data cannot be provided even in the long-term (for reasons
to do with the rarity or complexity of the disease). A CA is
issued on condition that the applicant will provide missing
data within an agreed timeframe after approval.
While OMP designation incentivizes drug development
for rare conditions, the rate of OMPs products reaching
the market has remained frustratingly flat [2]. Out of the
70 OMPs in Europe in the past decade, only 15 have re-
ceived exceptional circumstances (EC) authorization and
5 have been granted CA. This reflects the fact that many
OMPs do not or cannot meet the current criteria (see
above) for EC or CA.
There is a compelling case for exploring how the regula-
tory processes and healthcare systems can be used to sup-
port research and development whilst collecting the data
that is necessary to confirm the clinical profile of a prod-
uct and thus support patient access to OMPs that offer ac-
ceptable safety and effectiveness. Adaptive licensing is one
of a number of approaches currently proposed [3].
Features, rationale and potential impact of
adaptive licensing initiatives
The EMA’s ‘Road map to 2015’ states an intention to ex-
plore how the process that are run under the existing
regulatory legislation could be adapted to support
innovation [4]. The rationale for adaptive approaches to
licensing is to allow certain new therapies to be ap-
praised on the basis of an initial positive risk:benefit in a
small group of patients and to later confirm and broaden
this appraisal by using additional clinical data obtained
post approval from, for example, registries. This is then
reinforced by prospectively planned, adaptive and itera-
tive phases of evidence-gathering [3]. Adaptive licensing
differs from traditional dichotomous license decisions
where the presumption is that an experimental therapy,
on receiving a license, is safe and efficacious for use in a
given patient population [3-5]. The adaptive process
would involve a graded, tightly-managed market entry,
to account for higher risk and higher uncertainties than
that involved in the conventional licensing paradigm.
Although effected through a different model, the goals
and principles of adaptive licensing are in tune with the
reality of current drug evaluation paradigms, which
themselves involve, post-licence, a continuum of active
surveillance, additional studies, and capture and assess-
ment of real-life data. Patients with very rare and very
serious diseases for which there are no currently avail-
able therapies, might be expected to be more prepared
than other patient groups to accept the potential risks of
having earlier access to therapies while these are still be-
ing evaluated. We believe that some OMPs, aimed attreating certain rare conditions may be well suited to the
model provided by adaptive licensing.
Proponents of adaptive licensing view it as an evolu-
tionary step, extending elements of existing clinical de-
velopment and licensing programmes, and believe that
such an approach is vital to support and sustain the con-
tinued development and access to new and innovative
medicines. However concerns have been raised that such
a scheme would require a radical transformation in the
regulatory framework or would serve as a conduit for
premature drug approvals on commercial rather than
clinical grounds.
Patients’ perspective
Representatives of patients with rare diseases support
moves that would allow quicker access to safe and effica-
cious medicines but highlight the need for a pan-European
approach, before and after marketing authorization, to en-
sure that access, founded on clinical evaluation, is not frag-
mented at national level on grounds of cost considerations
taking precedence over clinical value and utility. Those with
rare diseases are aware that while the ideal is to seek a drug
license armed with a comprehensive clinical data dossier,
the reality of rare diseases requires clinical study in small
and heterogeneous patient populations, and must rely heav-
ily on real-life studies, registry reports and compassionate-
use programmes to prospectively generate sufficient data
for meaningful evaluation of drug efficacy and safety.
Regulator’s perspective
In considering the development of new treatments using
an adaptive model, the role of regulators changes from
‘gate-keeper’ to enabler. This will require open dialogue
with clinical experts, payers, industry and patients to pro-
vide the necessary environment, infrastructure and invest-
ment in anticipation of the confirmation of a product’s
effectiveness. Collaborative and horizon-scanning ap-
proaches will allow developing more innovative develop-
ment programmes and trial designs incorporating the most
appropriate endpoints, patient-reported outcomes and
quality of life measures by which to guide and gauge treat-
ment success. The existing mechanisms for “scientific
advice” are currently evolving to cover this enlarged scope.
Policy-makers’ perspective
Policy makers also appreciate that in rare disease settings,
therapeutic innovation is not always successfully translated
into patient benefits. The feasibility of flexible and innova-
tive clinical trial designs (including adaptive study designs),
and the timeframes for post-approval obligations need to
be collaboratively explored upfront. The concept of adap-
tive licensing is seen as pragmatic and encourages drug as-
sessment and approval as a continuum. In this continuum,
access to a therapeutic innovation may be possible earlier
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a novel therapy may differ from traditional approval and
appraisal routes. Organizations such as NICE are already
open to the submission of non-randomized controlled trial
evidence providing the inherent biases have been ad-
equately explored. There are also decision options that
allow for payment whilst the necessary confirmatory evi-
dence is being collected. It will be important however to
ensure that any time-efficiency gains are included in cost
considerations which need to encompass all development
costs in addition to drug pricing and cost-effectiveness
evaluations.Benefits, challenges and points of debate
Rare diseases represent uncharted territory and rarity
makes knowledge hard to obtain. In some instances, rare
diseases and their OMPs meet the criteria for EC and CA
and innovative products can be made available to patients
through these routes. However, often the patient charac-
teristics and the risk:benefit balance at stake in rare condi-
tions require a different paradigm and mechanisms. The
concept of adaptive licensing allows default to a progres-
sive regulatory assessment and quicker coordinated access
for OMPs. An additional benefit is greater engagement of
healthcare providers with the R&D process.
Potential challenges relate to managing the trade-off
between evidence-generation and access and in particular
the need to reconcile and develop a robust evidence-
collection system. Other challenges include determining
which specific OMPs and rare diseases might be eligible
for pilot schemes such as the EMA adaptive licensing
process, and devising mechanisms for deciding which
route and method of evidence collection best suits which
OMP and its disease setting. Flexible and innovative pri-
cing mechanisms based on real-life value assessment and
realized by contractual agreements could also address
country-specific issues of affordability.
Much needs to be done to move from the current con-
ceptual vision for adaptive licensing. This will require
political and cultural changes in thinking, such that all
stakeholders understand the risks, share the responsibil-
ities and make the investments necessary for the process
to be developed.
Close and frequent dialogue, interactions between the
sponsors, regulators, payers and patient groups should
be encouraged and formalized. The rewards for embra-
cing change and exploring new models will be found in
providing innovative treatments for patients with unmet
needs.
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